Sarthi Goyal is an investment research and M&A analyst with close to two years of experience supporting live deal mandates across healthcare and TMT. He is a CFA Level II candidate with CFA Level I cleared, and works across the full research cycle from target screening to client-facing deliverables.

Currently a Senior Associate at WNS, he supports senior deal teams on M&A mandates, building comp universes, running DCF and trading comps, and preparing pitchbooks and company profiles that go directly into live transactions.

At WNS, he covered the Novartis acquisition of Sandoz's neurology assets, building live deal materials that framed the strategic rationale and shareholder value case for a transaction carrying a 48% acquisition premium.

He also ran independent target screening for a European MedTech mandate with no initial criteria, reverse-engineering the acquirer's strategic priorities from prior deal history to build a shortlist that received a five-out-of-five feedback rating from the deal team.

Across more than 50 research deliverables, he has covered cardiovascular equipment, pharma technology, and broader healthcare sector dynamics.